Trial Profile
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Firtecan pegol (Primary) ; Cetuximab; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 16 Sep 2013 Results published in Cancer.
- 30 Jan 2012 Primary endpoint 'Progression-free-survival-duration' has been met.
- 01 Oct 2011 New source identified and integreated (M.D. Anderson Cancer Center).